Navigation Links
New Study Reports Improved Patient Outcomes for Breast Cancer Patients

VALENCIA, Calif., Feb. 18 /PRNewswire/ -- A new clinical study published this month in The Breast Journal (Vol. 15, No. 1) reports that high-quality patient outcomes for breast-conserving surgery can be achieved in the community hospital setting. This is one of the few and the most recent studies of its kind and is particularly relevant given that nearly two-thirds of all breast cancer patients in the United States are treated at community centers.

The study tracked 185 cases from 1997-2003 at Henry Mayo Newhall Memorial Hospital, located in the Southern California suburb of Valencia. The patients underwent a lumpectomy typically with a 5mm margin, as opposed to the 1-2mm margin performed in surgeries at most institutions. The study includes five-year follow-up data that shows a local recurrence rate of 2 percent as compared to the national norm of 4-9 percent.

"This study basically suggests a resetting of the bar on how to do lumpectomies and what patients can expect if it is done this way," said Henry Mayo's Breast Center Medical Director Gregory Senofsky, M.D. "Our findings are hard to ignore."

According to Barbara Florentine, M.D., medical director of the department of pathology at Henry Mayo and lead author of the study, the first objective of the study was to evaluate the factors known to influence outcomes. "These include tumor and patient characteristics, completeness of local surgical tumor excision, and adjuvant radiation therapy and/or chemotherapy/hormonal treatment," she says. "The second objective was to evaluate the percentage of cases in which the initial breast-conserving surgery did not achieve adequate surgical oncological results (5mm margins) and the number and type of subsequent surgeries that were required to achieve this goal."

Of the 185 cases tracked in this study, 87 percent had successful breast-conserving surgery. A single surgery was deemed sufficient to achieve the desired outcome in 54 percent of the cases while 46 percent required additional surgeries because of the 5mm requirement. Survival rates for patients undergoing this treatment at Henry Mayo compared favorably with data presented by the National Council Database reporting on outcomes at teaching/research hospitals. Disease free survival for early stage cancer was 91 percent at five years.

The flap-advancement reconstruction surgery performed by Dr. Senofsky requires a team that includes a specially trained surgeon and radiologist plus the presence of a pathologist in the operating room to provide real-time information. "The procedure requires extra work and extra training in how radiologists insert the wires and how surgeons approach their craft relative to performing larger targeted lumpectomies with excellent cosmetic results, but it is what patients should come to expect based on our study," he said.

"It is difficult to successfully obtain adequate excision of the cancer while still maintaining a beautiful breast with no distortions--and that's very important to a woman," stated Dr. Florentine. "Dr. Senofsky is able to achieve both through the use of oncoplastic techniques."

While Henry Mayo has no comprehensive breast center building, the hospital does provide equivalent services thanks to a well-integrated medical campus and a multi-modality breast team that meets regularly to discuss care plans tailored to the uniqueness of each patient, including age, health status, risk factors, and the patient's own desires and needs. The hospital owns and operates the pathology, breast imaging, and inpatient and outpatient surgical operating suites while on-campus radiation, medical oncology and breast surgery services are provided by independent physician groups.

The study was conducted by a nine-person investigative team, six of whom are affiliated with Henry Mayo. Leading the study were Drs. Senofsky and Barbara Florentine. In addition to his role at Henry Mayo, Dr. Senofsky is a clinical faculty member at UCLA's surgical oncology department and the author of The Patient's Guide to Outstanding Breast Cancer Care. Dr. Florentine is medical director of the department of pathology and is affiliated with the department of pathology at the Keck School of Medicine at the University of Southern California. Additional Henry Mayo participants include physicians John Barstis, M.D.; Alexander Black, M.D.; and Robert Zimmerman, M.D., along with Brian Cooper, tumor registrar officer.

ABOUT HENRY MAYO - Henry Mayo Newhall Memorial Hospital is a 221-bed not-for-profit acute-care hospital serving the Santa Clarita Valley since 1975. Services include trauma, emergency, intensive care, maternity, surgery, nursing, wound care, behavioral health, and acute rehab as well as cancer, cardiology, imaging, lab, digestive, respiratory services, and physical and occupational therapies. For information, visit or call 661-253-8000.

SOURCE Henry Mayo Newhall Memorial Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):